Involvement of phosphodiesterases in autoimmune diseases

Journal of Neuroimmunology

Volumn 220, Issue 1-2, 2010, Pages 43-51

  Mizrachi, Keren ^a,b   Aricha, Revital ^a   Feferman, Tali ^a   Kela Madar, Neta ^a   Mandel, Ilana ^c   Paperna, Tamar ^c   Miller, Ariel ^c,d   Ben Nun, Avraham ^a   Berrih Aknin, Sonia ^e   Souroujon, Miriam C ^a,f   Fuchs, Sara ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

^e CNRS   (France)

^f OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Experimental allergic encephalomyelitis (EAE); Experimental autoimmune myasthenia gravis (EAMG); Multiple sclerosis (MS); Myasthenia gravis (MG); Phosphodiesterases (PDE)

Indexed keywords

PHOSPHODIESTERASE;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME REGULATION; FEMALE; HUMAN; MULTIPLE SCLEROSIS; MUSCLE INJURY; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT;

ADOLESCENT; ADULT; ANIMALS; BIOLOGICAL MARKERS; CHILD; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; ISOENZYMES; MULTIPLE SCLEROSIS; MUSCULAR ATROPHY; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PHOSPHORIC DIESTER HYDROLASES; PREDICTIVE VALUE OF TESTS; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; UP-REGULATION; YOUNG ADULT;

EID: 77649181513     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.12.012     Document Type: Article

References (58)

1. Aharonov A., Tarrab-Hazdai R., Silman I., and Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 14 (1977) 129-137
2. Anaya J.M., and Espinoza L.R. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J. Rheumatol. 22 (1995) 595-599
3. Aricha R., Feferman T., Souroujon M.C., and Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. Faseb J. 20 (2006) 374-376
4. Bailey S.L., Schreiner B., McMahon E.J., and Miller S.D. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 8 (2007) 172-180
5. Barabitskaja O., Foulke Jr. J.S., Pati S., Bodor J., and Reitz Jr. M.S. Suppression of MIP-1beta transcription in human T cells is regulated by inducible cAMP early repressor (ICER). J. Leukoc. Biol. 79 (2006) 378-387
6. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
7. Bender A.T., Ostenson C.L., Giordano D., and Beavo J.A. Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression. Cell. Signal. 16 (2004) 365-374
8. Bielekova B., Lincoln A., McFarland H., and Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 164 (2000) 1117-1124
9. Bopp T., Becker C., Klein M., Klein-Hessling S., Palmetshofer A., Serfling E., Heib V., Becker M., Kubach J., Schmitt S., Stoll S., Schild H., Staege M.S., Stassen M., Jonuleit H., and Schmitt E. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204 (2007) 1303-1310
10. Borger P., Kauffman H.F., Postma D.S., and Vellenga E. Interleukin-4 gene expression in activated human T lymphocytes is regulated by the cyclic adenosine monophosphate-dependent signaling pathway. Blood 87 (1996) 691-698
11. Bright J.J., Du C., Coon M., Sriram S., and Klaus S.J. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J. Immunol. 161 (1998) 7015-7022
12. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
13. Deibler G.E., Martenson R.E., and Kies M.W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2 (1972) 139-165
14. Deval C., Mordier S., Obled C., Bechet D., Combaret L., Attaix D., and Ferrara M. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem. J. 360 (2001) 143-150
15. D'Hellencourt C.L., Diaw L., Cornillet P., and Guenounou M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int. J. Immunopharmacol. 18 (1996) 739-748
16. Dinter H., Tse J., Halks-Miller M., Asarnow D., Onuffer J., Faulds D., Mitrovic B., Kirsch G., Laurent H., Esperling P., Seidelmann D., Ottow E., Schneider H., Tuohy V.K., Wachtel H., and Perez H.D. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J. Neuroimmunol. 108 (2000) 136-146
17. Dominguez-Jimenez C., Sancho D., Nieto M., Montoya M.C., Barreiro O., Sanchez-Madrid F., and Gonzalez-Amaro R. Effect of pentoxifylline on polarization and migration of human leukocytes. J. Leukoc. Biol. 71 (2002) 588-596
18. Dong R.P., Umezawa Y., Ikushima H., Munakata Y., Schlossman S.F., and Morimoto C. Different regulatory effects of pentoxifylline on human T cell activation pathways. J. Clin. Immunol. 17 (1997) 247-252
19. Ekholm D., Hemmer B., Gao G., Vergelli M., Martin R., and Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J. Immunol. 159 (1997) 1520-1529
20. Feferman T., Aricha R., Mizrachi K., Geron E., Alon R., Souroujon M.C., and Fuchs S. Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3. J. Neuroimmunol. 209 (2009) 87-95
21. Fleming C.M., He H., Ciota A., Perkins D., and Finn P.W. Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness. J. Immunol. 167 (2001) 1703-1711
22. Folcik V.A., Smith T., O'Bryant S., Kawczak J.A., Zhu B., Sakurai H., Kajiwara A., Staddon J.M., Glabinski A., Chernosky A.L., Tani M., Johnson J.M., Tuohy V.K., Rubin L.L., and Ransohoff R.M. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol. 97 (1999) 119-128
23. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., and Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50 (2001) 443-451
24. Galindo-Rodriguez G., Bustamante R., Esquivel-Nava G., Salazar-Exaire D., Vela-Ojeda J., Vadillo-Buenfil M., and Avina-Zubieta J.A. Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J. Rheumatol. 30 (2003) 2382-2384
25. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., and Rudensky A.Y. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007) 771-775
26. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., Kowalczyk D., and Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300 (2002) 559-566
27. Hinkle R.T., Dolan E., Cody D.B., Bauer M.B., and Isfort R.J. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle Nerve 32 (2005) 775-781
28. Hofstetter H.H., Karulin A.Y., Forsthuber T.G., Ott P.A., Tary-Lehmann M., and Lehmann P.V. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J. Neuroimmunol. 170 (2005) 105-114
29. Hurwitz R.L., Hirsch K.M., Clark D.J., Holcombe V.N., and Hurwitz M.Y. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. J. Biol. Chem. 265 (1990) 8901-8907
30. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9 (1988) 222-229
31. Kanda N., and Watanabe S. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem. Pharmacol. 62 (2001) 495-507
32. Koh W.S., Yang K.H., and Kaminski N.E. Cyclic AMP is an essential factor in immune responses. Biochem. Biophys. Res. Commun. 206 (1995) 703-709
33. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariety J., and Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104 (2001) 197-202
34. Lennon V.A., Lambert E.H., Leiby K.R., Okarma T.B., and Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146 (1991) 2245-2248
35. Lerner A., and Epstein P.M. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem. J. 393 (2006) 21-41
36. Ma R., Yang B.Y., and Wu C.Y. A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells. Int. Immunopharmacol. 8 (2008) 1408-1417
37. MacDonald M.J., Shahidi N.T., Allen D.B., Lustig R.H., Mitchell T.L., and Cornwell S.T. Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus. Jama 271 (1994) 27-28
38. Maksymowych W.P., Avina-Zubieta A., Luong M.H., and Russell A.S. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J. Rheumatol. 22 (1995) 625-629
39. Menon R.T., Feferman T., Aricha R., Souroujon M.C., and Fuchs S. Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent. J. Neuroimmunol. 201-202 (2008) 128-135
40. Moore C.S., Earl N., Frenette R., Styhler A., Mancini J.A., Nicholson D.W., Hebb A.L., Owens T., and Robertson G.S. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydrox ypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826, 141) prevents experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 319 (2006) 63-72
41. Mor F., and Cohen I.R. Pathogenicity of T cells responsive to diverse cryptic epitopes of myelin basic protein in the Lewis rat. J. Immunol. 155 (1995) 3693-3699
42. Navegantes L.C., Resano N.M., Migliorini R.H., and Kettelhut I.C. Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E663-E668
43. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
44. Reyes-Irisarri E., Sanchez A.J., Garcia-Merino J.A., and Mengod G. Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 66 (2007) 923-931
45. Rieckmann P., Weber F., Gunther A., Martin S., Bitsch A., Broocks A., Kitze B., Weber T., Borner T., and Poser S. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64 (1996) 193-200
46. Rott O., Cash E., and Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23 (1993) 1745-1751
47. Sadhu K., Hensley K., Florio V.A., and Wolda S.L. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J. Histochem. Cytochem. 47 (1999) 895-906
48. Seybold J., Thomas D., Witzenrath M., Boral S., Hocke A.C., Burger A., Hatzelmann A., Tenor H., Schudt C., Krull M., Schutte H., Hippenstiel S., and Suttorp N. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105 (2005) 3569-3576
49. Shichijo M., Shimizu Y., Hiramatsu K., Inagaki N., Tagaki K., and Nagai H. Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation. Int. Arch. Allergy Immunol. 114 (1997) 348-353
50. Silva J.C., Rocha M.F., Lima A.A., Brito G.A., de Menezes D.B., and Rao V.S. Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis. Inflamm. Res. 49 (2000) 14-19
51. Skapenko A., Leipe J., Lipsky P.E., and Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res. Ther. 7 Suppl 2 (2005) S4-S14
52. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Loschmann P.A., and Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79 (1997) 54-61
53. Tasken K., and Ruppelt A. Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts. Front. Biosci. 11 (2006) 2929-2939
54. Tasken K., and Stokka A.J. The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem. Soc. Trans. 34 (2006) 476-479
55. Torgersen K.M., Vang T., Abrahamsen H., Yaqub S., and Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell. Signal. 14 (2002) 1-9
56. Voltz R., Hohlfeld R., Fateh-Moghadam A., Witt T.N., Wick M., Reimers C., Siegele B., and Wekerle H. Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671. Neurology 41 (1991) 1836-1838
57. Wacholtz M.C., Minakuchi R., and Lipsky P.E. Characterization of the 3′,5′-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cell. Immunol. 135 (1991) 285-298
58. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 65 (2009) 239-248